AZD 1656

Drug Profile

AZD 1656

Alternative Names: AZD1656

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 14 Sep 2011 Final pharmacodynamics, pharmacokinetics and adverse events data from a phase I trial in Type-2 diabetes mellitus and two clinical trials in healthy Western and Japanese volunteers presented at the (47th Annual meeting of the European Association for the Study of Diabetes (EASD-2011) ,
  • 01 Aug 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top